IL15 and neoplasm: We administered two doses of the IL-15/IL-15Ra complex (IL-15cplx) (43) or phosphate-buffered saline (PBS) to the mice bearing RMA-KR tumors according to the protocol outlined in Fig. 7D, and NK cell function was tested the day after the second injection, which corresponded to end-stage tumor growth.